TREM2 and prostate cancer: Genetic inactivation of the Apoe or Trem2 genes or the use of the histone deacetylase inhibitor romidepsin to specifically eliminate senescent neutrophils has been shown to effectively slow the progression of prostate cancer in mouse models (49).